Starpharma and Mundipharma have signed a licence agreement for the sales and marketing rights to VivaGel BV for 43 countries in Europe, Russia, the Commonwealth of Independent States (CIS) and the balance of countries in Latin America.
Takeda Pharmaceutical has agreed to divest its its majority shareholding of 51.34% in Guangdong Techpool Bio-Pharma (Techpool), a China-based firm focused on urinary protein biopharmaceuticals and production of biopharmaceuticals in critical care, to its joint venture (JV) partners for $280m.
Accent Therapeutics has been launched with $40m Series A financing for precision cancer treatments targeting RNA-modifying proteins.
Amryt has signed an agreement with Aegerion Pharmaceuticals to expand its exclusive licence agreement for Lojuxta (lomitapide) into Russia and the Commonwealth of Independent States (CIS), as well as the non-EU Balkan states.
Takeda Pharmaceutical has agreed to acquire Ireland-based rare disease biotech company Shire in a cash-cum stock deal worth around £45.3bn.
Alkermes has launched a new competitive awards program called the ALKERMES Pathways Research Awards Program to support the next generation of researchers working on the front lines to advance understanding and awareness of central nervous system (CNS) disorders.
Endo International has agreed to acquire New Jersey-based Somerset Therapeutics, that develops and markets sterile injectable and ophthalmic drugs, and the business of its India-based affiliate Wintac, which operates as Somerset's contract developer and manufacturer.
Shire’s board said that it is willing to recommend Takeda Pharmaceutical’s revised acquisition offer of £46bn to its shareholders.
Synpromics has partnered with Lonza Pharma & Biotech to further develop its inducible promoter system and enhance manufacturing of biopharmaceuticals.
Germany-based Fresenius Kabi has scrapped its $4.3bn merger agreement with Akorn, saying that the US generic drugmaker did not fulfill various closing conditions.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.